跳到正文
原文
openFDA 药品召回·· 7 天前精选AI 评分58

费森尤斯医疗召回2.5%葡萄糖腹膜透析液,主袋微孔渗漏致无菌保障不足

DELFLEX Peritoneal Dialysis Solution with 2.5% Dextrose, Low Magnesium/ Low Calcium and Attached stay"safe Exchange Set, 2,500 mL Single dose bag, Sterile and Non-Pyrogenic, Rx only, CAT. NO. 054-25322. Fresenius Medical Care, Renal Therapies Group, LLC, Lawrence, MA 01843. NDC 46163-209-94

AI 导读

openFDA公布费森尤斯医疗(Fresenius Medical Care)召回DELFLEX腹膜透析液(含2.5%葡萄糖、低镁低钙,配stay safe交换管路,2,500 mL单剂量袋,NDC 46163-209-94,CAT. NO. 054-25322)。召回原因为缺乏无菌保障,涉事批次收到投诉称主袋印刷区存在微小穿孔可能导致渗漏。

推荐理由

召回原因指向主袋印刷区微孔可能渗漏,读者可据此了解该批腹膜透析液的无菌保障风险。

来源:openFDA 药品召回 · api.fda.gov